Renal protection against ischaemia-reperfusion injury in transplantation

Lead Research Organisation: University College London

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

Scientific Abstract Design: Multicentre double-blind randomised controlled trial Setting: Kidney transplant units in the UK and Holland Target population: Patients undergoing living donor kidney transplantation Intervention being evaluated: Intermittent limb ischaemia to induce remote ischaemic preconditioning prior to kidney transplantation Measurement of outcomes and duration of follow up Primary outcome: glomerular filtration rate (GFR) 12 months after transplantation Secondary outcomes 1.Time for serum creatinine to fall by 50% 2.eGFR 6 months after transplantation 3.Kidney graft cortical tubulointerstitial fibrosis at 6 months (digital analysis of Sirius red staining in biopsy material) 4.RIPC-induced protein expressional changes in kidney tissue 5.Incidence of delayed graft function (serum creatinine levels increase, remain unchanged, or decrease less than 10% per day in three consecutive days in the first week after transplantation) 6.Incidence of acute rejection during the first 12 months after transplantation 7.Long-term outcomes using renal registry data 2-5 years after transplantation (serum creatinine/eGFR, graft survival, patient survival) Duration of follow-up:1 year within the trial, 5 year follow-up using renal registry data Sample size: Randomisation (8:6:6:3 schedule) will be between control (n=135), late RIPC (n=100), dual RIPC (n=100) and recipient-only RIPC (n=50) , recruiting 385 patients in total. For the primary analysis, this gives 80% power to detect a 10% difference in GFR at 12 months between control and late/dual RIPC. This also enables secondary analyses, with 80% power to detect a 12.5% difference in GFR at 12 months, and a 15% difference in the time for creatinine to halve post-transplantation between between late RIPC and dual RIPC. An exploratory comparison will be made between control and recipient-only RIPC; 50 patients in this group gives 80% power to detect a 20% difference in the time for creatinine to halve post-transplantation. Planned analysis: There is no interim analysis; final analysis of primary and all secondary end-points will be at 12 months, with the exception of GFR at 2-5 years Project timetables including recruitment rates: -4 to 0 months: ethics and R+D approval 0 to 3 months: trial set-up at each centre, research nurse recruitment and training, case report form design and preparation 4 to 12 months; recruit the first 150 patients 12 to 24 months; follow up of first 150 patients and recruitment of further 200 patients 24 to 39 months; recruitment of 30 patients, completion of annual follow up 33 to 42 months; data collection, tissue analysis, trial closure and unblinding, and data analysis.
 
Description CLRN funding for NHS support North Central London CLRN
Amount £160,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 10/2010 
End 10/2012
 
Description New trial centres 
Organisation Ghent University Hospital
Department Department of Nephrology
Country Belgium 
Sector Academic/University 
PI Contribution WE opened two new recruitment centres in 2012
Collaborator Contribution Recruiting patients
Impact Nil
Start Year 2012